Validation of a Test for Fetal Malformations

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1943 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-09-30

Study Completion Date

2017-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators have developed a diagnostic test for the evaluation of the presence of fetal malformations through metabolomic analysis of maternal peripheral blood serum by chromatographic techniques and mass spectrometry, and subsequent mathematical modeling analysis of the data by means of multivariate mathematical models specifically developed for this purpose. The study aims at determining the performance parameters (specificity, sensibility, positive predictive value (PPN), negative predictive value (NPV), etc.) of the test and its applicability. To do this, the investigators will use the serum samples of the patients enrolled in New Zealand in the SCOPE Study (www.scopestudy.net), an international study conducted between years 2004-2008.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation and Validation of New Biomarkers by Mass Spectrometry

NCT01025973

Diabetes Mellitus

COMPLETED

Development of Non-invasive Prenatal Test for Microdeletion and Other Genetic Syndromes Based on Cell Free DNA

NCT02109770

Microdeletion Syndromes Trisomy 21 Trisomy 18 +2 more

COMPLETED

Fetal Cell Analysis From Maternal Blood

NCT05671744

Prenatal Screening Pregnancy Related Genetic Disease

UNKNOWN NA

Development of a Prenatal Test for Fetal Aneuploidy Detection

NCT01451671

Fetal Complications

COMPLETED

Development of Non-invasive Prenatal Screening Test for Microdeletions Based on Fetal DNA Isolated From Maternal Blood

NCT01852708

Trisomy 21 Trisomy 18 Trisomy 13 +2 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The test has been developed in a case-control study. In this clinical trial the investigators will test it in a large cohort that is likely to resemble a real population. The purpose of validation is to see if the test is able to recognize the few malformed fetuses in the entire population and especially its specificity in real conditions. In addition, the investigators will check whether particular maternal conditions (such as preeclampsia, gestational diabetes, etc.) or fetal conditions (Small for gestational age, Large for gestational age, etc.) affect the test results.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Fetal Anomaly

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

19-21 weeks' gestation

The test validation will be performed on the 1943 serum samples of pregnant women at 19-21 weeks' gestation recruited in New Zealand for the SCOPE Study.

All the samples will be analyzed to extract and purify the whole metabolome. Metabolites will be characterized through mass spectrometric techniques. These data will be interpreted by means of a bioinformatic algorithm specifically designed for this purpose.

Serum metabolomics profiling

Intervention Type OTHER

The serum samples will be used to get a metabolomic profile

14-16 weeks' gestation

Five hundred subjects at 14-16 weeks gestation were randomly selected from the whole cohort of patients. The serum samples collected at 14-16 weeks gestation will be used to test the diagnostic performance at this earlier gestational phase.

Serum metabolomics profiling

Intervention Type OTHER

The serum samples will be used to get a metabolomic profile

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Serum metabolomics profiling

The serum samples will be used to get a metabolomic profile

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\- Nulliparous women, with a singleton pregnancy, between 14wks, 0 days and 16wks, 6 days gestation who give informed consent to participate in SCOPE.

Exclusion Criteria

* Unsure of last menstrual period (LMP)
* Unwilling to have ultrasound scan at ≤20 weeks
* ≥3 miscarriages
* ≥3 terminations
* Essential hypertension treated pre-pregnancy
* Moderate-severe hypertension at booking ≥160/100 mmHg
* Diabetes
* Renal disease
* Systemic lupus erythematosus
* Anti-phospholipid syndrome
* Sickle cell disease
* HIV positive
* Major uterine anomaly
* Cervical suture
* Knife cone biopsy
* Ruptured membranes now
* Long term steroids
* Treatment low-dose aspirin
* Treatment calcium (\>1g/24h)
* Treatment eicosapentanoic acid (fish oil)
* Treatment vitamin C ≥1000 mg \& Vit E ≥400 iu
* Treatment heparin/low molecular weight heparin

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes